两部门印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》（2025年）

Core Viewpoint - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have issued new drug directories for basic medical insurance, maternity insurance, work injury insurance, and commercial health insurance, effective from January 1, 2026, replacing the previous 2024 directories [1] Group 1: New Drug Directories - The new drug directories will be strictly enforced by local authorities, prohibiting any adjustments to the types, notes, or classifications of drugs within the directories [1] - The updated directories require timely updates to information systems and databases, ensuring that newly added drugs are included and removed drugs are deleted as per regulations [1] - Adjustments to the "notes" of drugs must be updated in the payment scope, and there is a need for synchronization with drug coding databases and intelligent supervision subsystems [1] Group 2: Transition Period for Excluded Drugs - Drugs that were not successfully renewed and removed from the directory will have a 6-month transition period to ensure continuity of medication [1] - During this transition period, which lasts until the end of June 2026, the medical insurance fund will continue to pay at the original payment standards for these drugs [1] - Local coordinating regions are required to implement effective measures to facilitate the transition and guide designated medical institutions in timely replacements [1]